

July 24, 2018



# Aptose To Release Second Quarter Ended June 30, 2018 Financial Results and Hold Conference Call on August 7, 2018

SAN DIEGO and TORONTO, July 24, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, will release its financial results for the quarter ended June 30, 2018 on Tuesday, August 7, 2018 at 5:00 pm Eastern time.

***Conference Call & Webcast:***

***Tuesday, August 7, 2018 @ 5:00 pm Eastern time***

Toll-Free: (844) 882-7834

International: (574) 990-9707

Passcode: 2693419

Webcast: <https://edge.media-server.com/m6/p/8qrt4qyn>

***Replays available through August 14, 2018***

Toll-Free: (855) 859-2056

Replay Passcode: 2693419

The live conference call can also be accessed through a link on the Investor Relations section of Aptose's website at [ir.aptose.com](http://ir.aptose.com). Please log onto the webcast at least 10 minutes prior to the start of the call to ensure time for any software downloads that may be required. An archived version of the webcast along with a transcript will be available on the company's website for 30 days.

The press release, the financial statements and the management's discussion and analysis for the quarter ended June 30, 2018 will be available on SEDAR at [www.sedar.com](http://www.sedar.com) and EDGAR at [www.sec.gov/edgar.shtml](http://www.sec.gov/edgar.shtml)

## **About Aptose Biosciences Inc.**

Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. APTO-253, the only clinical stage inhibitor of MYC oncogene expression, is in a Phase 1b clinical trial for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or high risk MDS. CG-806 is an oral, first-in-class pan-FLT3/pan-BTK multi-cluster kinase inhibitor expected to reach IND submission by the end of 2018 and is planned for development to treat AML and certain B cell malignancies. For further information, please visit [www.aptose.com](http://www.aptose.com).

For further information, please contact:

**Aptose Biosciences**

Greg Chow, CFO  
647-479-9828  
Email: [gchow@aptose.com](mailto:gchow@aptose.com)

**SMP Communications**

Susan Pietropaolo  
201-923-2049  
[susan@smpcommunications.com](mailto:susan@smpcommunications.com)

**LifeSci Advisors**

Michael Wood  
Managing Director  
646-597-6983  
[mwood@lifesciadvisors.com](mailto:mwood@lifesciadvisors.com)



Source: Aptose Biosciences, Inc.